Next-generation testing for cancer risk: Perceptions, experiences, and needs among early adopters in community healthcare settings

Genetic Testing and Molecular Biomarkers

Volumn 19, Issue 12, 2015, Pages 657-665

  Blazer, Kathleen R ^a   Nehoray, Bita ^a   Solomon, Ilana ^a   Niell Swiller, Mariana ^a   Culver, Julie O ^a   Uman, Gwen C ^b   Weitzel, Jeffrey N ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Vital Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; COUNSELING; EDUCATION; GENE INACTIVATION; HUMAN; MAJOR CLINICAL STUDY; NEXT GENERATION SEQUENCING; PENETRANCE; PERCEPTION; SKILL; COMMUNITY CARE; FEMALE; GENETIC SCREENING; GENETICS; HIGH THROUGHPUT SEQUENCING; MALE; NEOPLASMS; PATIENT EDUCATION; QUESTIONNAIRE;

COMMUNITY HEALTH SERVICES; FEMALE; GENETIC TESTING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; NEOPLASMS; PATIENT EDUCATION AS TOPIC; SURVEYS AND QUESTIONNAIRES;

EID: 84949945899     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2015.0061     Document Type: Article

References (49)

1. Azvolinsky A (2013) Supreme Court ruling broadens BRCA testing options. J Natl Cancer Inst 105: 1671-1672
2. Berg JS, Khoury MJ, Evans JP (2011) Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet Med 13: 499-504
3. Biesecker LG (2012) Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project. Genet Med 14: 393-398
4. Biesecker LG, Burke W, Kohane I, et al. (2012) Nextgeneration sequencing in the clinic: are we ready? Nat Rev Genet 13: 818-824
5. Blazer KR, Christie C, Uman G, et al. (2012) Impact of webbased case conferencing on cancer genetics training outcomes for community-based clinicians. J Cancer Educ 27: 217-225
6. Blazer KR, MacDonald DJ, Culver JO, et al. (2011) Personalized cancer genetics training for personalized medicine: improving community-based healthcare through a genetically literate workforce. Genet Med 13: 832-840
7. Blazer KR, MacDonald DJ, Ricker C, et al. (2005) Outcomes from intensive training in genetic cancer risk counseling for clinicians. Genet Med 7: 40-47
8. Borzekowski DL, Guan Y, Smith KC, et al. (2014) The Angelina effect: immediate reach, grasp, and impact of going public. Genet Med 16: 516-521
9. Collins F (2010) Has the revolution arrived? Nature 464: 674-675
10. Creswell JW (2003) Mixed methods procedures. In: Research Design Qualitative, Quantitative, and Mixed Method Approaches. 2nd edn. Sage Publications, Thousand Oaks, CA, pp 208-225
11. Culver JO, Brinkerhoff CD, Clague J, et al. (2013) Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress. Clin Genet 84: 464-472
12. Cypowyj C, Eisinger F, Huiart L, et al. (2009) Subjective interpretation of inconclusive BRCA1/2 cancer genetic test results and transmission of information to the relatives. Psychooncology 18: 209-215
13. DeMarco TA, Smith KL, Nusbaum RH, et al. (2007) Practical aspects of delivering hereditary cancer risk counseling. Semin Oncol 34: 369-378
14. Dewey FE, Grove ME, Pan C, et al. (2014) Clinical interpretation and implications of whole-genome sequencing. JAMA 311: 1035-1045
15. Domchek SM, Bradbury A, Garber JE, et al. (2013) Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol 31: 1267-1270
16. Euhus DM, Robinson L (2013) Genetic predisposition syndromes and their management. Surg Clin North Am 93: 341-362
17. Evans JP, Rothschild BB (2012) Return of results: not that complicated? Genet Med 14: 358-360
18. Feero WG (2014) Clinical application of whole-genome sequencing: proceed with care. JAMA 311: 1017-1019
19. Gray SW, Hicks-Courant K, Cronin A, et al. (2014) Physicians attitudes about multiplex tumor genomic testing. J Clin Oncol 32: 1317-1323
20. Green ED, Guyer MS (2011) Charting a course for genomic medicine from base pairs to bedside. Nature 470: 204-213
21. Hampel H, Sweet K, Westman JA, et al. (2004) Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet 41: 81-91
22. Hilbers F, Vreeswijk M, van Asperen C, et al. (2013) The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation? Clin Genet 84: 407-414
23. Hiraki S, Rinella ES, Schnabel F, et al. (2014) Cancer risk assessment using genetic panel testing: considerations for clinical application. J Genet Couns 23: 604-617
24. Hodgson SV, Foulkes WD, Eng C, et al. (2007) A Practical Guide to Human Cancer Genetics. Cambridge University Press, New York, NY.
25. Khoury MJ, Clauser SB, Freedman AN, et al. (2011) Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century. Cancer Epidemiol Biomarkers Prev 20: 2105-2114
26. Ku CS, Cooper DN, Wu M, et al. (2012) Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol 25: 1055-1068
27. Kurian AW, Hare EE, Mills MA, et al. (2014) Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32: 2001-2009
28. Langreth R, Pettypiece S (2013). Myriad Gene Patent Ruling Triggers Race for Cancer Tests. Bloomberg, New York City, NY.
29. Lawrence WF, Peshkin BN, Liang W, et al. (2001) Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations. Cancer Epidemiol Biomarkers Prev 10: 475-481
30. Lindor NM, McMaster ML, Lindor CJ, et al. (2008) Concise handbook of familial cancer susceptibility syndromes. 2nd edition. J Natl Cancer Inst Monogr: 1-93
31. MacConaill LE, Garraway LA (2010) Clinical implications of the cancer genome. J Clin Oncol 28: 5219-5228
32. MacDonald DJ, Blazer KR, Weitzel JN (2010) Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: the power of partnership. J Natl Compr Canc Netw 8: 615-624
33. Mardis ER (2011) A decade s perspective on DNA sequencing technology. Nature 470: 198-203
34. Mauer CB, Pirzadeh-Miller SM, Robinson LD, et al. (2014 The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genet Med 16: 407-412
35. Meiser B (2005) Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psycho-Oncology 14: 1060-1074
36. Murray ML, Cerrato F, Bennett RL, et al. (2011) Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Genet Med 13: 998-1005
37. Offit K (1998) Clinical Cancer Genetics: Risk Counseling and Management. Wiley-Liss, New York, NY.
38. O Neill S, Rubinstein W, Sener S, et al. (2009) Psychological impact of recall in high-risk breast MRI screening. Breast Cancer Res Treat 115: 365-371
39. Ormond KE, Wheeler MT, Hudgins L, et al. (2010) Challenges in the clinical application of whole-genome sequencing. Lancet 375: 1749-1751
40. Patenaude AF, Dorval M, DiGianni LS, et al. (2006) Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol 24: 700-706
41. Petrucelli N, Lazebnik N, Huelsman KM, et al. (2002) Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice. Genet Test 6: 107-113
42. Plon SE, Eccles DM, Easton D, et al. (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29: 1282-1291
43. Pritchard CC, Smith C, Salipante SJ, et al. (2012) ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 14: 357-366
44. Schwartz GF, Hughes KS, Lynch HT, et al. (2008) Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer 113: 2627-2637
45. Selkirk CG, Vogel KJ, Newlin AC, et al. (2014). Cancer genetic testing panels for inherited cancer susceptibility: the clinical experience of a large adult genetics practice. Fam Cancer 13: 527-536
46. Vos J, Oosterwijk JC, Gomez-Garcia E, et al. (2011) Perceiving cancer-risks and heredity-likelihood in genetic-counseling: how counselees recall and interpret BRCA 1/2-Test results. Clin Genet 79: 207-218
47. Vos J, Otten W, van Asperen C, et al. (2008) The counsellees view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life. Psychooncology 17: 822-830
48. Walsh T, Casadei S, Lee MK, et al. (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 108: 18032-18037
49. Weitzel JN, Blazer KR, MacDonald DJ, et al. (2011) Genetics, genomics and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin 61: 327-359